Yes, Medicare does cover BCG for bladder cancer. Bacillus Calmette-Guérin intravesical therapy is paid under Medicare Part B because a clinician instills it through a catheter during an office or outpatient visit rather than the patient taking it at home. After you meet the annual Part B deductible, you pay 20% coinsurance on the Medicare-approved amount for each treatment session.1Healthline. Does Medicare Cover Bladder Cancer
What You Pay Under Original Medicare
BCG treatment for non-muscle invasive bladder cancer typically runs on a long schedule: a six-week induction course followed by maintenance instillations that can stretch across one to three years.2Cleveland Clinic. Bacillus Calmette-Guerin (BCG) Treatment Every one of those instillations is billed to Part B, and so are the follow-up cystoscopies and lab work that go with them.
For 2026, the Part B cost structure looks like this:
- Annual Part B deductible: $283, paid once per year before Medicare starts covering its share.3Medicare.gov. Medicare Costs
- Coinsurance: 20% of the Medicare-approved amount for each session after the deductible.4GoodRx. Does Medicare Cover Immunotherapy
- Standard monthly Part B premium: $202.90, with higher-income beneficiaries paying more.3Medicare.gov. Medicare Costs
Because the drug and its administration are both billed under Part B, and because the treatment course is long, cumulative out-of-pocket costs can be significant. One 2021 study cited a median cost of roughly $29,000 in the first year and more than $117,000 over five years for the full course of bladder cancer treatment. A beneficiary on Original Medicare with no supplemental coverage would owe 20% of the Medicare-approved portion of those charges.1Healthline. Does Medicare Cover Bladder Cancer
If BCG happens to be administered during an inpatient hospital stay, Part A picks it up as part of the hospitalization, with a per-benefit-period deductible instead of per-service coinsurance.5Medicare.gov. Medicare Coverage of Cancer Treatment Services In practice, almost all BCG instillations happen in a urologist’s office, so Part B is the relevant program.
Part D Does Not Cover BCG
Do not expect your prescription drug plan to pay for BCG. Part D covers drugs patients take on their own, primarily orals filled at a pharmacy. BCG is a clinician-administered drug, and patients who have submitted claims under Part D have been denied on the ground that it “does not meet the definition of a Medicare Part D drug request.”6Inspire. Denial of BCG Coverage Under Prescription Medicare Part D The urologist’s office bills BCG directly through Part B.
Medicare Advantage: Same Coverage, Different Rules
Medicare Advantage (Part C) plans must cover everything Original Medicare covers, so BCG therapy is included in every plan.7GoodRx. BCG Vaccine Medicare Coverage The mechanics of getting the treatment and what you pay can look different, though:
- Network limits. Most Advantage plans are HMOs or PPOs, and using an out-of-network urologist or infusion site can mean higher costs or no coverage.
- Prior authorization. Advantage plans may require approval before treatment begins, which Original Medicare does not.
- Referrals. HMO-type plans may require a referral from your primary care physician before you see a specialist.
- Cost-sharing. Copays and coinsurance are set by the plan and do not follow the standard 20% Part B structure.
Check the plan’s Summary of Benefits or call member services before your first instillation to confirm authorization requirements and what you will owe per session.7GoodRx. BCG Vaccine Medicare Coverage
How Medigap Handles the 20%
If you are on Original Medicare, a Medigap (Medicare Supplement) policy can cover the coinsurance and deductibles that Part B leaves you with. Medigap Plan G, one of the most popular options for people who became eligible for Medicare after January 1, 2020, pays the full 20% Part B coinsurance for outpatient cancer treatment once the annual $283 deductible has been met. It also covers Part A hospital deductibles and copays for any inpatient stays connected to treatment.8Triage Cancer. Medigap Quick Guide Medigap plans have no provider networks, so you can see any urologist or facility that accepts Original Medicare.9Boomer Benefits. Medicare Plan G
The strongest window to enroll in a Medigap policy is the six-month open enrollment period that begins the month you turn 65 and enroll in Part B. Outside that window, insurers can charge more or deny coverage based on health. And Medigap is not available if you are enrolled in a Medicare Advantage plan; the two are separate coverage paths.8Triage Cancer. Medigap Quick Guide
The BCG Shortage and Your Share of the Cost
BCG has been in short supply for over a decade. Merck is the sole U.S. manufacturer of TICE BCG, and demand has outstripped production since another manufacturer stopped making it in 2012.10BCAN. BCG Shortage and Bladder Cancer To keep patients treated, urologists often use reduced doses or split vials among patients.
Medicare adjusted its billing to fit that reality. In July 2019, CMS introduced HCPCS code J9030, which bills BCG per milligram instead of per instillation.11CMS. Transmittal 4320, Change Request 11296 The provider reports the milligrams actually administered, and Medicare reimburses accordingly.12CMS. Billing and Coding: Intravesical Instillation of BCG For you, that means a reduced-dose session produces proportionally lower coinsurance than a full 81 mg dose. In April 2025, the FDA also authorized an expanded access program for ImmunityBio’s recombinant BCG to help fill the supply gap.13Mayo Clinic Connect. BCG Shortage Since 2019 May Be Resolved Soon
Coverage When BCG Isn’t an Option
When BCG is unavailable or the cancer stops responding to it, Medicare covers several alternative intravesical therapies under Part B as medically necessary cancer treatment.
Adstiladrin (nadofaragene firadenovec-vncg), FDA-approved in December 2022 for high-risk, BCG-unresponsive NMIBC, is billed under HCPCS code J9029 and given once every three months by catheter. Some plans require prior authorization.14Aetna. Intravesical Therapy for Bladder Cancer15CareSource. Medicare Multi-Policy Pharmacy: Adstiladrin
Anktiva (nogapendekin alfa), used alongside BCG for BCG-unresponsive NMIBC, received permanent HCPCS code J9028 effective January 1, 2025. Medicare reimburses it at 106% of the Average Sales Price, and CMS granted the drug Transitional Pass-Through status under the Outpatient Prospective Payment System through at least September 2027, which allows separate Medicare reimbursement.16ImmunityBio. ImmunityBio Announces Permanent J-Code for Anktiva17Anktiva. Access and Reimbursement Guide
Valrubicin (Valstar), an older intravesical chemotherapy for BCG-refractory carcinoma in situ in patients who are not candidates for immediate bladder removal, is billed under HCPCS code J9357. Some plans require prior authorization.18Atrio Health Plans. Anti-Neoplastics Valstar Part B PA Request Form
INLEXZO (gemcitabine intravesical system), FDA-approved in September 2025 for BCG-unresponsive NMIBC, received permanent HCPCS code J9183 effective April 1, 2026, giving Medicare and commercial payers a standardized billing pathway.19Johnson & Johnson. INLEXZO Assigned Permanent Billing Code
Other chemotherapy drugs used intravesically for NMIBC, including mitomycin, gemcitabine, and docetaxel in their standard formulations, are generally eligible for Part B coverage when a provider administers them, though specific coverage determinations can vary by Medicare Administrative Contractor.
Related Services Medicare Covers
Diagnostic and monitoring services around BCG treatment are covered too. Cystoscopy, the standard procedure for checking the bladder and watching for recurrence, is covered under Part B as a medically necessary diagnostic procedure.20Medical News Today. Does Medicare Cover Bladder Cancer CMS updated payment rates in January 2023 to improve access to Blue Light Cystoscopy with Cysview, a more sensitive detection technology.21UroToday. CMS Improves Medicare Reimbursement for Blue Light Cystoscopy
Bladder tumor marker tests are covered for diagnosed patients being monitored for recurrence: Medicare allows up to four tests per year in the first two years after diagnosis, tapering to one per year by year five.22CMS. LCD: Bladder Tumor Markers Medicare does not cover routine bladder cancer screening for people without symptoms, because no screening test has been shown to improve survival in the general population.20Medical News Today. Does Medicare Cover Bladder Cancer